Ana Alarcon Tomas

17PUBLICATIONS
94CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)HaematologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Apr 14, 2025
CAR T-cell therapy response varies by extranodal disease site in large B-cell lymphoma.

Alejandro Luna, Sean M Devlin, Kai Rejeski

|Apr 01, 2025
An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma.

Sandeep S Raj, Teng Fei, Shalev Fried

|Oct 25, 2024
Severe ICANS after CAR T-cell therapy and assessment of prevention with levetiracetam for seizure prophylaxis following CAR T-cell for DLBCL & PMBCL in Europe: a survey on behalf of the Cellular Therapy & Immunobiology Working Party (CTIWP) of the EBMT.

Piera Angelillo, Ana Alarcon Tomas, Edoardo Campodonico

|Sep 11, 2024
Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma.

Harper Hubbeling, Doris Leithner, Emily A Silverman

|Jun 11, 2024
CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas.

Gustav Y Cederquist, Javin Schefflein, Sean M Devlin

|Jul 31, 2023
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma.

Michael Scordo, Jessica R Flynn, Mithat Gonen

Pageof 3

Frequent Collaborators

16 joint publications

Miguel-Ángel Perales

9 joint publications

Richard J Lin

8 joint publications

Sergio Giralt

7 joint publications

Gunjan Shah